Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) were down 2.9% during trading on Wednesday . The stock traded as low as $7.74 and last traded at $7.75. Approximately 163,179 shares changed hands during trading, a decline of 82% from the average daily volume of 927,578 shares. The stock had previously closed at $7.98.
Analysts Set New Price Targets
A number of brokerages recently weighed in on VYGR. Wells Fargo & Company upgraded shares of Voyager Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their price target for the stock from $9.00 to $14.00 in a research report on Tuesday, January 2nd. Guggenheim assumed coverage on Voyager Therapeutics in a research report on Tuesday, March 26th. They set a "buy" rating and a $22.00 target price on the stock. HC Wainwright started coverage on Voyager Therapeutics in a report on Tuesday, March 19th. They set a "buy" rating and a $30.00 target price for the company. Citigroup began coverage on Voyager Therapeutics in a research note on Thursday, March 7th. They issued a "buy" rating and a $16.00 price target on the stock. Finally, StockNews.com raised shares of Voyager Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, March 9th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $19.33.
View Our Latest Stock Analysis on Voyager Therapeutics
Voyager Therapeutics Stock Performance
The firm has a 50 day moving average of $8.79 and a 200-day moving average of $7.95. The stock has a market capitalization of $420.28 million, a PE ratio of 2.50 and a beta of 0.96.
Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 28th. The company reported $1.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $1.84. The business had revenue of $90.06 million during the quarter, compared to analyst estimates of $4.95 million. Voyager Therapeutics had a net margin of 52.93% and a return on equity of 63.89%. On average, sell-side analysts predict that Voyager Therapeutics, Inc. will post -1.64 earnings per share for the current year.
Institutional Investors Weigh In On Voyager Therapeutics
Institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of Voyager Therapeutics by 1.9% during the fourth quarter. Vanguard Group Inc. now owns 2,529,668 shares of the company's stock worth $21,350,000 after acquiring an additional 47,711 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Voyager Therapeutics by 27.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 180,025 shares of the company's stock worth $1,519,000 after purchasing an additional 38,906 shares in the last quarter. Barclays PLC raised its stake in shares of Voyager Therapeutics by 261.6% during the 4th quarter. Barclays PLC now owns 66,201 shares of the company's stock worth $559,000 after purchasing an additional 47,892 shares in the last quarter. Bridgeway Capital Management LLC acquired a new stake in shares of Voyager Therapeutics during the 4th quarter valued at about $1,526,000. Finally, Royal Bank of Canada grew its stake in shares of Voyager Therapeutics by 85.5% in the 4th quarter. Royal Bank of Canada now owns 12,017 shares of the company's stock valued at $101,000 after buying an additional 5,540 shares in the last quarter. Institutional investors and hedge funds own 48.03% of the company's stock.
About Voyager Therapeutics
(
Get Free Report)
Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.
Recommended Stories
Before you consider Voyager Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.
While Voyager Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
